Merck & Co., Inc. (MRK)
| Market Cap | 264.21B |
| Revenue (ttm) | 64.24B |
| Net Income (ttm) | 19.03B |
| Shares Out | 2.48B |
| EPS (ttm) | 7.56 |
| PE Ratio | 14.09 |
| Forward PE | 12.32 |
| Dividend | $3.40 (3.19%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 5,335,050 |
| Open | 105.37 |
| Previous Close | 105.04 |
| Day's Range | 105.28 - 106.95 |
| 52-Week Range | 73.31 - 106.95 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 111.93 (+5.15%) |
| Earnings Date | Feb 3, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $111.93, which is an increase of 5.15% from the latest price.
News
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy
The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill and its cancer therapy, making them the latest additions to the fast-track pr...
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case
Merck is reiterated as a buy, with the price target raised to $114, reflecting robust Q3 results and strong technical momentum. Q3 saw non-GAAP EPS of $2.58 (vs. $2.35 consensus) and revenue of $17.3B...
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE: MRK) drugs with potential blockbuster sales.
Exclusive: US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers
The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by Reuters.
Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for c...
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month...
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) ...
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human ...
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive dos...
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United...
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydu...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript
Top 10 High-Yield Dividend Stocks For December 2025
The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks ...
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025.